NEJM COVID Ethics - Crisis triage, how do we decide, not discriminate against disability, understand quality of life from the patient perspective, and apply prognostic estimates to a new disease?
Wednesday, May 20, 2020 - 21:48
BMJ hydroxychloroquine treatment at 600 mg/day in hospitalised patients with with COVID-19 requiring O2 was not associated with decrease ICU admission or 21-day survival after hospital admission compared with standard care
Wednesday, May 20, 2020 - 20:32
JC JAMA retrospective study of 1438 hospitalised patients with COVID-19 receiving hydroxychloroquine with or without azithromycin reported no significant difference in mortality
Wednesday, May 20, 2020 - 18:28
JC NEJM Observational propensity matched study of hydroxychloroquine use in patients with COVID-19 and moderate-severe respiratory illness, reported no association of benefit or harm with relation to primary outcome or death or intubation